Calcineurin subunit B is not an effective adjuvant when combined with a novel HBV protein particle vaccine.
- Author:
Xia CHUAI
1
;
Hong CHEN
;
Wen WANG
;
Yao DENG
;
Li RUAN
;
Wen-Jie TAN
Author Information
1. National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
- Publication Type:Journal Article
- MeSH:
Adjuvants, Immunologic;
pharmacology;
Animals;
Calcineurin;
pharmacology;
Female;
Hepatitis B Vaccines;
immunology;
Mice;
Mice, Inbred C57BL;
Protein Subunits
- From:
Chinese Journal of Virology
2014;30(5):554-560
- CountryChina
- Language:Chinese
-
Abstract:
To compare different adjuvant formulation and explore the impact of Calcineurin B subunit(CnB) as adjuvant with a novel HBV protein particle (HBSS1) vaccine in mice, female C57BL/6 mice were immunized HBSS1 with Al(OH)3 only, or a normal dose (5 μg) CnB only, or (CnB+ Al(OH)3) mixture as the adjuvant. All immunized groups were primed twice at 4-week intervals; followed by boosting with recombinant adenoviral based HBV vaccine(rAdSS1) at 10-week intervals. We detected the antigen specific humoral response in mice, including total IgG antibody and IgG subtyping. Then, we characterized the specific cell-mediated immune (CMI) response by detection of γ-interferon secreting splenocytes after stimulaton with S or PreS1 peptide pools. No enhancement of immunity was found among the mice with 5 μg of CnB alone or combined with Al(OH), adjuvanted vaccine,which could not induce higher level of anti-PreS1 and anti-S antibodies and CMI than that of HBSS1 alone or Al(OH)3 adjuvanted vaccines. We concluded that CnB is not an effective adjuvant for a novel HBV subunit vaccine.
